{"title":"某多学科医院2019-2021年直接作用抗凝剂和口服抗凝剂成本增加的药物经济学特征","authors":"E. R. Kadyseva, L. Kulagina","doi":"10.33920/med-03-2208-20","DOIUrl":null,"url":null,"abstract":"The purpose of the work is to analyze the costs of direct-acting anticoagulants and oral anticoagulants from the total cost of medicines by years in a multidisciplinary hospital, as well as to calculate the cost of a daily prophylactic dose of drugs on the example of apixaban and sodium heparin","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacoeconomic features of increased costs of direct-acting and oral anticoagulants in a multidisciplinary hospital in 2019–2021\",\"authors\":\"E. R. Kadyseva, L. Kulagina\",\"doi\":\"10.33920/med-03-2208-20\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose of the work is to analyze the costs of direct-acting anticoagulants and oral anticoagulants from the total cost of medicines by years in a multidisciplinary hospital, as well as to calculate the cost of a daily prophylactic dose of drugs on the example of apixaban and sodium heparin\",\"PeriodicalId\":406478,\"journal\":{\"name\":\"Glavvrač (Chief Medical Officer)\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Glavvrač (Chief Medical Officer)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33920/med-03-2208-20\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-03-2208-20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacoeconomic features of increased costs of direct-acting and oral anticoagulants in a multidisciplinary hospital in 2019–2021
The purpose of the work is to analyze the costs of direct-acting anticoagulants and oral anticoagulants from the total cost of medicines by years in a multidisciplinary hospital, as well as to calculate the cost of a daily prophylactic dose of drugs on the example of apixaban and sodium heparin
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
